Literature DB >> 21673030

Serum antibody response following genital {alpha}9 human papillomavirus infection in young men.

Zoe R Edelstein1, Joseph J Carter, Ruchi Garg, Rachel L Winer, Qinghua Feng, Denise A Galloway, Laura A Koutsky.   

Abstract

Background. Although the prevalence of human papillomavirus (HPV) genital infection is similarly high in males and females, seroprevalence is lower in males. This study assessed rates and determinants of seroconversion after detection of genital HPV infection in young men. Methods. We investigated HPV type-specific seroconversion in a cohort of heterosexual male university students who had an α9 HPV type (HPV-16, -31, -33, -35, -52, -58, or -67) detected in the genital tract (n = 156). HPV DNA and antibodies were detected and typed using liquid bead-based multiplex assays. We calculated seroconversion using Kaplan-Meier survival analysis. Cox proportional hazards models with generalized estimating equations were used to examine associations with seroconversion. Results. Within 24 months of detecting genital HPV infection, type-specific seroconversion ranged from 4% for HPV-52 to 36% for HPV-31. HPV-16 seroconversion at 24 months was 13% (95% confidence interval [CI], 7%-25%). Among incident HPV infections, ever cigarette smoking and infection site(s) (shaft/scrotum and glans/urine vs shaft/scrotum or glans/urine only) were positively associated with type-specific seroconversion. Conclusions. For each of the α9 HPV types, type-specific seroconversion within 24 months was observed in 36% or less of infected men. Seroconversion might be related to cigarette smoking and genital site(s) infected.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21673030      PMCID: PMC3114468          DOI: 10.1093/infdis/jir242

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men.

Authors:  M E Hagensee; N Kiviat; C W Critchlow; S E Hawes; J Kuypers; S Holte; D A Galloway
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

2.  Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.

Authors:  T D de Gruijl; H J Bontkes; J M Walboomers; J T Schiller; M J Stukart; B S Groot; M M Chabaud; A J Remmink; R H Verheijen; T J Helmerhorst; C J Meijer; R J Scheper
Journal:  J Natl Cancer Inst       Date:  1997-05-07       Impact factor: 13.506

3.  HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas.

Authors:  Aimée R Kreimer; Gary M Clifford; Peter J F Snijders; Xavier Castellsagué; Chris J L M Meijer; Michael Pawlita; Raphael Viscidi; Rolando Herrero; Silvia Franceschi
Journal:  Int J Cancer       Date:  2005-06-10       Impact factor: 7.396

4.  Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease.

Authors:  Janet R Daling; Margaret M Madeleine; Lisa G Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall; John N Krieger
Journal:  Int J Cancer       Date:  2005-09-10       Impact factor: 7.396

5.  Natural history of cervicovaginal papillomavirus infection in young women.

Authors:  G Y Ho; R Bierman; L Beardsley; C J Chang; R D Burk
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

6.  Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers.

Authors:  Susanne Krüger Kjaer; Christian Munk; Jeanette Falck Winther; Hans Ole Jørgensen; Chris J L M Meijer; Adriaan J C van den Brule
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-06       Impact factor: 4.254

7.  Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women.

Authors:  E I Svare; S K Kjaer; B Nonnenmacher; A M Worm; H Moi; R B Christensen; A J van den Brule; J M Walboomers; C J Meijer; N L Hubbert; D R Lowy; J T Schiller
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

8.  Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men.

Authors:  Martín Lajous; Nancy Mueller; Aurelio Cruz-Valdéz; Luis Victor Aguilar; Silvia Franceschi; Mauricio Hernández-Avila; Eduardo Lazcano-Ponce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

9.  Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States.

Authors:  Deborah L Thompson; John M Douglas; Mark Foster; Michael E Hagensee; Carolyn Diguiseppi; Anna E Barón; Jennifer E Cameron; Timothy C Spencer; Jonathan Zenilman; C Kevin Malotte; Gail Bolan; Mary L Kamb; Thomas A Peterman
Journal:  J Infect Dis       Date:  2004-09-23       Impact factor: 5.226

10.  Regional distribution and incidence of human papillomavirus infections among heterosexual men and women with multiple sexual partners: a prospective study.

Authors:  G J Van Doornum; M Prins; L H Juffermans; C Hooykaas; J A van den Hoek; R A Coutinho; W G Quint
Journal:  Genitourin Med       Date:  1994-08
View more
  24 in total

Review 1.  Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.

Authors:  John Berry; Sean C Glasgow
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

2.  NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men.

Authors:  Anil K Chaturvedi; Barry I Graubard; Tatevik Broutian; Robert K L Pickard; Zhen-Yue Tong; Weihong Xiao; Lisa Kahle; Maura L Gillison
Journal:  Cancer Res       Date:  2015-04-14       Impact factor: 12.701

Review 3.  Should female sex workers be offered HPV vaccination?

Authors:  Maarten F Schim van der Loeff; Alex Vorsters; Elske Marra; Pierre Van Damme; Arjan Hogewoning
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 4.  EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection.

Authors:  Anna R Giuliano; Alan G Nyitray; Aimée R Kreimer; Christine M Pierce Campbell; Marc T Goodman; Staci L Sudenga; Joseph Monsonego; Silvia Franceschi
Journal:  Int J Cancer       Date:  2014-07-26       Impact factor: 7.396

5.  Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.

Authors:  Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Sex Transm Dis       Date:  2016-03       Impact factor: 2.830

6.  Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia.

Authors:  Rachel A Katzenellenbogen; Joseph J Carter; Joshua E Stern; Melinda S Butsch Kovacic; Parinda A Mehta; Sharon L Sauter; Denise A Galloway; Rachel L Winer
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

7.  Spontaneous cervicovaginal lesions and immune cell infiltrates in nonhuman primates.

Authors:  Carole E Harbison; Mary E Ellis; Susan V Westmoreland
Journal:  Toxicol Pathol       Date:  2013-02-20       Impact factor: 1.902

8.  Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.

Authors:  Tsung-Chieh Jane Fu; Joseph J Carter; James P Hughes; Qinghua Feng; Stephen E Hawes; Stephen M Schwartz; Long Fu Xi; Taylor Lasof; Joshua E Stern; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Int J Cancer       Date:  2016-08-04       Impact factor: 7.396

Review 9.  Tumour virus vaccines: hepatitis B virus and human papillomavirus.

Authors:  Margaret Stanley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

Review 10.  HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee.

Authors:  Chantal Sauvageau; Christine Dufour-Turbis
Journal:  Hum Vaccin Immunother       Date:  2015-11-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.